Regen BioPharma, Inc. Engages Charles River Laboratories to Initiate FDA-Requested Study to Support Initiation of HemaXellerate Clinical Trial

SAN DIEGO, CA--Regen BioPharma, Inc. (OTCBBRGBP) (OTC PINKRGBP) announced today that it has engaged Charles River Laboratories to initiate a Good Laboratory Practices (GLP) mouse toxicity study with regards to HemaXellerate. HemaXellerate, a therapy under development by Regen, is a cellular drug designed to heal damaged bone marrow.

After consultations with the FDA as well as its Scientific Advisory Board members, Regen BioPharma has developed a protocol for assessing safety of the HemaXellerate product in mice lacking an immune system. The protocol was reviewed by the FDA before finalization. This sophisticated animal model is commonly used in cell therapy research as a last safety assessment before products are allowed to enter clinical trials.

"We are enthusiastic about initiating what we hope to be the last phase of experimentation before the HemaXellerate aplastic anemia trial can begin", said David Koos, Chairman & CEO of Regen BioPharma. "Working with the team at Charles River in establishing the protocol and timetable has been very productive. We look forward to rapid and efficient completion of the laboratory experimental phase of this program."

Charles River Laboratories is a NYSE-traded company with 8,500 employees, established in 1947 specializing in a variety of pre-clinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. The company has facilities in Canada, Belgium, Finland, France, Germany, Hungary, Italy, Ireland, China, Japan, the Netherlands, Spain, and the United Kingdom.

"As with any cellular therapy, safety is our top-most priority. The decision to engage Charles River, a premier contract research organization, to perform these fundamental experiments was based on extensive discussions and deliberations between our Scientific Advisory Board members as well as external industry experts," said Thomas Ichim, PhD, Chief Scientific Officer of Regen BioPharma. "We are confident that working with an industry leader like Charles River will allow for seamless execution of the experimental protocol and a clear path to initiation of the clinical trials."

ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBBRGBP) (OTC PINKRGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.



    Regen BioPharma Inc. 
    David R. Koos, PhD 
    Chairman & Chief Executive Officer
    619-702-1404 Phone
    619-330-2328 Fax


Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.